Navigation Links
Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
Date:7/28/2008

PITTSBURGH, July 28 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nisoldipine Extended-release (ER) Tablets, 20 mg, 30 mg and 40 mg.

Nisoldipine ER Tablets, indicated for the treatment of hypertension, are the generic version of Sciele Pharma's Sular(R) ER Tablets, which had annual U.S. sales of approximately $94 million for the 12 months ending March 31, 2008, for these three strengths. Mylan's Nisoldipine ER, which is being shipped immediately, is the first generic version of Sular ER to be introduced in the United States.

Currently, Mylan has 93 ANDAs pending FDA approval, 21 of which are potential first-to-file opportunities.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
10. Novozymes Launches Enzyme to Reduce Acrylamide in Food
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
(Date:5/5/2015)... , May 5, 2015 CytomX, a ... cancer, today announced that Sean McCarthy , D. ... Suisse Antibody Day in New York ... Dr. McCarthy will present an overview of CytomX,s Probody ... drug conjugate programs. About CytomX Therapeutics ...
(Date:5/5/2015)... , May 5, 2015   Tocagen Inc. ... David R. Parkinson , M.D., a venture ... appointed to the board of directors of Tocagen. ... experience in oncology clinical development, including leading clinical ... global approvals of the cancer therapeutics Gleevec®, Femara®, ...
(Date:5/5/2015)... 05, 2015 GEA Pharma Systems, ... as recipients of the INTERPHEX Exhibitor Awards for ... their Portable, Continuous, Miniature and Modular (PCMM) platform. ... footprint, continuous processing equipment, smart control systems and ... powders and inactive ingredients into bulk tablets. ...
Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3
... ALXA ) announced today the company,s,participation and that Thomas B. King, Alexza ... Conference: NewsMakers in the Biotech Industry ... Center ... Presentation Date: Thursday, September 4, 2008 Presentation Time: ...
... Provider Doubles Sales Over Same Period Last ... ... Aug. 27 MedPro Imaging, a premier,provider of economical ultrasound solutions, ... of sales,over the same period last year. Recent installations include Norwegian,American ...
... of The Kavli Prize will be celebrated with a special ... prize to the seven Kavli laureates. Acclaimed scientists in the ... the week. , , Note: The award ceremony, lectures and symposia ... at 11.15 AM (CET), September 9, in Oslo Concert Hall ...
Cached Biology Technology:Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 2Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 3MedPro Installs 1000th Ultrasound System Worldwide 2Inaugural Kavli Prize ceremony and symposia: Sept. 8-11 (Oslo, Norway) 2Inaugural Kavli Prize ceremony and symposia: Sept. 8-11 (Oslo, Norway) 3
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... to the recovery efforts following the devastating effects of the ... assess damage within the reactor,s core. A study in the ... from Los Alamos National Laboratory (LANL) shows that muon imaging ... reactor cores and locating the melted fuel. Muon imaging, ...
... can convert a wide variety of vegetable and animal fats ... -- into a key ingredient for making plastics that currently ... process appears in the journal ACS Sustainable Chemistry & ... that many of the plastics found in hundreds of everyday ...
... have a limited capacity to soak up atmospheric carbon ... University. The study, available online in the journal ... atmospheric carbon dioxide could alter the carbon and nitrogen ... woodland plots over an 11-year period, the researchers found ...
Cached Biology News:Getting to the core of Fukushima 2
CMRL Medium-1066 (1X) liquid...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
... The PowerEase 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple intuitive ...
...
Biology Products: